骨髓增生异常综合征的分子生物学研究进展  

Molecular biology for myelodysplastic syndrome:an update

作　　者：罗静[1] 刘林[1] 王利[1] 

机构地区：[1]重庆医科大学附属第一医院血液科,重庆400016

出　　处：《肿瘤》2012年第2期137-141,共5页Tumor

基　　金：国家自然科学基金面上资助项目(编号:30971277);重庆市自然科学基金资助项目(编号:2009JJ0424)

摘　　要：骨髓增生异常综合征(myelodysplastic syndrome,MDS)的发病机制目前尚不完全清楚,可能主要与MDS的高度异质性密切相关。研究显示,致病基因异常表达、表观遗传学异常及造血干细胞的异常等分子生物学改变都与MDS的发病密切相关。因此,本文拟对近年来发现的一些与MDS发病密切相关的分子生物学特性的改变作一综述。The pathogenesis of myelodysplastic syndrome（MDS） has not been fully clarified,it may be closely associated with the great heterogeneity in biology that characterizes this group of diseases.Recent studies have revealed that some changes in molecular biology,including abnormal expression of disease gene,abnormal epigenetics,and abnormalities of hematopoietic stem cells,were closely correlated with the pathogenesis of MDS.This article reviews the newly discovered changes of molecular and biological characteristics associated with the development of MDS.

关 键 词：血液肿瘤 骨髓增生异常-骨髓增生症 肿瘤标记 生物学 

分 类 号：R551.3[医药卫生—血液循环系统疾病]